Molecular Diagnostics Market worth $30.74 billion by 2030
The report "Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) - Global Forecast to 2030", is valued at an estimated USD 19.48 billion in 2025 and is projected to reach USD 30.74 billion by 2030 at a CAGR of 9.6% during the forecast period.
Browse 772 market data Tables and 61 Figures spread through 539 Pages and in-depth TOC on "Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), and Application (Infectious (Hepatitis, HIV, HAI, Flu), Cancer (Breast, Lung)) - Global Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html
The molecular diagnostics market is experiencing steady growth, supported by several key factors. One of the primary factors is the rise in research and development funding, which is accelerating innovation and enabling the development of more advanced testing technologies. At the same time, increasing awareness about the benefits of early disease detection, especially for conditions like infections and cancer, encourages patients and providers to rely more on molecular testing. These tests offer faster and more accurate results, helping effectively guide treatment decisions. The growing emphasis on personalized medicine also contributes to the market’s expansion. With healthcare access and infrastructure improvement in emerging economies, molecular diagnostics is becoming more widely adopted across different settings. As these trends continue, the market is expected to grow in the coming years.
By test type, the lab tests segment accounted for a significant share in 2024.
By test type, the molecular diagnostics market is divided into lab tests and PoC tests. The lab tests segment accounted for the largest market in 2024. This is primarily due to the widespread use of molecular testing in centralized laboratories, which handle high patient volumes and require advanced, high-throughput platforms. Lab tests offer superior accuracy, sensitivity, and broad assay menus, which make them suitable for complex applications, such as cancer diagnostics, genetic screening, and infectious disease detection. These tests are well-integrated into hospital and reference lab workflows, supported by trained personnel and quality control protocols. The continued development of automated systems and multiplex technologies further enhances lab testing efficiency. Their established infrastructure and clinical reliability continue to drive their dominance in the market.
By sample type, the blood, serum, and plasma segment is projected to be the fastest-growing market during the forecast period.
By sample type, the molecular diagnostics market is segmented into blood, serum & plasma; urine; and other samples. The blood, serum, and plasma segment is projected to be the fastest-growing market during the forecast period. This growth is driven by the broad clinical applicability of these samples in detecting infectious diseases, genetic disorders, and cancer. These sample types are widely accepted in clinical practice due to their reliability, ease of collection, and compatibility with various molecular testing platforms. Advancements in liquid biopsy and non-invasive testing methods further support the use of blood-based diagnostics. As the demand for accurate and minimally invasive testing increases, the segment is expected to continue its rapid expansion.
North America represents the largest regional molecular diagnostics market.
The molecular diagnostics market has been segmented into five geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is estimated to be the largest regional market for molecular diagnostics, supported by a strong healthcare infrastructure and high adoption of advanced testing technologies. The region sees a significant burden of infectious diseases, cancer, and genetic disorders, driving the demand for accurate and timely diagnostics. Favorable regulatory policies and consistent investments in research and development further contribute to market growth. Major diagnostic companies and well-equipped laboratories enable large-scale deployment of molecular tests across hospitals and clinical labs. Additionally, structured reimbursement systems and widespread awareness about early diagnosis support the region's continued use of molecular diagnostics.
Major players operating in the molecular diagnostics market are Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Limited (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
